Biocept joins the Russell Microcap Index

Biocept Inc (NASDAQ:BIOC) (FRA:B003) announced that it was added to the Russell Microcap Index as the US market opened on June 28, 2021.  The Russell Microcap Index is a broadly used performance benchmark for smaller growth stocks in the US. Membership, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell, a leading global index provider, determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.  “This is an exceptionally exciting time with the full commercial launch underway of our novel, proprietary CNSide assay that provides physicians with a significantly improved tool to diagnose and manage patients with tumors that have metastasized to the central nervous system,” Biocept president and CEO Michael Nall said.  “We believe the addition to the Russell Microcap Index will further raise awareness of Biocept within the global investment community.”  WATCH: Biocept excited to partner with Quest Diagnostics to offer its liquid biopsy testing for lung cancer Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Around $10.6 trillion in assets are benchmarked against Russell’s US indexes. Biocept develops and performs molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Contact the author at stephen.gunnion@proactiveinvestors.com